Deutsche Bank Upgrades MAP Pharmaceuticals (MAPP) to Buy
More News related to AZN
- U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
- AstraZeneca and the Philadelphia Department of Public Health Provide Free Medicines to Pennsylvania's Uninsured
- AstraZeneca (AZN) Submits NDA to U.S. FDA for Ticagrelor
- AstraZeneca Submits US New Drug Application for Ticagrelor (BRILINTA(TM)), an Investigational Antiplatelet Agent
- Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body
More News related to MAPP
- MAP Pharma. (MAPP) Secures $60M Equity Financing Facility with Azimuth Opportunity
- MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility
- MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- MAP Pharmaceuticals Reports Third Quarter of 2009 Financial Results
- MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients
Deutsche Bank upgrades MAP Pharmaceuticals (Nasdaq: MAPP) to Buy. Price target increased from $5 to $12.
Deutsche analyst says, "Despite the significant share appreciation following the announcement of the Levadex Phase 3 results, MAP's modest $185M equity valuation still appears attractive, given our view that Levadex could potentially generate US sales in excess of $250M at peak, if approved. Moreover, as we had previously removed UDB from our model (following disappointing Ph 3 data), there is potential for upside if AstraZeneca (NYSE: AZN) remains committed to its partnership with MAP for UDB. Given this outlook, we are upgrading MAP shares to Buy from Hold."
To see more analyst ratings on MAPP Click Here.
MAP Pharmaceuticals, Inc. uses inhalation technologies to improve the therapeutic benefits and commercial attractiveness of drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.
Related Categories
UpgradesStocks Mentioned
-0.37
+0.23Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
